CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer

Lian,Weisheng; Ouyang,Yong

doi:10.3892/ol.2017.5921

CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer

Authors:
- Weisheng Lian
- Yong Ouyang
View Affiliations

Affiliations: Department of Intervention, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Vascular Surgery, Hangzhou First People's Hospital of Fuyang, Hangzhou, Zhejiang 311499, P.R. China
Published online on: March 27, 2017 https://doi.org/10.3892/ol.2017.5921
Pages: 3415-3422
Copyright: © Lian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the rates of detection and the positive rates of computed tomography (CT)-guided aspiration of lung biopsy for epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) gene, and analyzed the relationship between gene mutation and clinical characteristics to improve the rate of related factors of gene detection. The clinical data and CT-guided aspiration biopsy specimen of 250 patients with lung cancer. Data showed that the rate of EGFR gene mutation was 41.2% (103/250) in biopsy specimens of non-small cell lung cancer patients. The rate of EGFR gene mutation of adenocarcinoma (56.6%, P<0.01) was higher than other types of lung cancer. ALK gene mutation of patients in phase IV was obviously higher than that of patients not in phase IV (18.5 and 1.8%, P<0.01). The rate of EGFR gene detection was 83.2% (208/250). The rate of detection of tumor cells >50 was higher. The rate of ALK protein immunohistochemical detection was 87.2%, and the rate of coarse needle biopsy detection was higher than that of the fine needle (91 and 72%, P<0.01), but the positive rate between coarse needle biopsy and fine needle biopsy had no difference (P>0.05). The rate of detection was associated with tumor cell number (P<0.05), and had no correlation with the proportion of tumor cells (P>0.05). The rate of detection of EGFR and ALK genes was associated with tumor cell number and had no correlation with the proportion of tumor cells. The rate of detection is higher when the number of tumor cells is more than 50.

View Figures

View References

1	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zeng H and Zhang S: Epidemiology of lung cancer in China. Thorac Cancer. 6:209–215. 2015. View Article : Google Scholar : PubMed/NCBI
3	Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, et al: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 354:99–105. 1999. View Article : Google Scholar : PubMed/NCBI
4	Dimitroulis J and Stathopoulos GP: Evolution of non-small cell lung cancer chemotherapy (Review). Oncol Rep. 13:923–930. 2005.PubMed/NCBI
5	Donati V, Fontanini G, Dell'Omodarme M, Prati MC, Nuti S, Lucchi M, Mussi A, Fabbri M, Basolo F, Croce CM, et al: WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res. 13:884–891. 2007. View Article : Google Scholar : PubMed/NCBI
6	Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, et al: Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 25:2741–2746. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ma PC: Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med. 79:(Electronic Suppl 1). eS56–eS60. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zhu Z and Chai Y: Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib. Thorac Cancer. 7:681–683. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
10	Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, et al: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer. 11:12011. View Article : Google Scholar : PubMed/NCBI
11	Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
12	Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Watkins C, Duffield E, Armour A and Mok T: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol (ASCO Annual Meeting). 27:Abst 8006. 2009.
13	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
14	Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS and Shaw AT: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 10:232–236. 2015. View Article : Google Scholar : PubMed/NCBI
15	Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, Mohammed S, Miyagi Y, Matsukuma S, Sekine Y and Fujisawa T: Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest. 132:597–602. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, Yoshino I, et al: EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 16:4938–4945. 2010. View Article : Google Scholar : PubMed/NCBI
17	Duan H, Lu J, Lu T, Gao J, Zhang J, Xu Y, Wang M, Wu H, Liang Z and Liu T: Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. Int J Clin Exp Pathol. 8:13136–13145. 2015.PubMed/NCBI
18	Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, Nakajima T, Mano H and Takeuchi K: KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 7:e313232012. View Article : Google Scholar : PubMed/NCBI
19	Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, Erickson-Johnson MR, Caron BL, Li Y, Tang H, et al: Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol. 6:459–465. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X and Lu N: Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 24:2589–2593. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lee JK, Kim TM, Koh Y, Lee SH, Kim DW, Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, et al: Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer. 77:460–463. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li H, Boiselle PM, Shepard JO, Trotman-Dickenson B and McLoud TC: Diagnostic accuracy and safety of CT-guided percutaneous needle aspiration biopsy of the lung: comparison of small and large pulmonary nodules. AJR Am J Roentgenol. 167:105–109. 1996. View Article : Google Scholar : PubMed/NCBI
23	Soria JC, Massard C and Le Chevalier T: Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 21:2324–2332. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nakahara Y, Mochiduki Y, Miyamoto Y, Nakahara Y and Katsura Y: Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer. 104:1271–1280. 2005. View Article : Google Scholar : PubMed/NCBI
25	Rubin BP, Heinrich MC and Corless CL: Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007. View Article : Google Scholar : PubMed/NCBI
26	Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
27	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
28	Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
29	Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI